Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
KRTX Stock Summary
Top 10 Correlated ETFs
KRTX
In the News
Karuna's (KRTX) Q4 Loss Widens, Focus on Bristol Myers Buyout
Karuna's (KRTX) fourth-quarter 2023 earnings and revenues miss estimates. The company is set to be acquired by Bristol Myers.
Bullish Continuation in '24? 3 Market Areas to Watch
Will stocks continue into 2024? Stock Strategist Andrew Rocco shares his prediction and unveils 3 important market areas to monitor.
Yes Virginia, There Is a Santa Claus Rally
The Russell is up an astounding +26% from late October, largely thanks to signaled interest rate cuts from the Fed in 2024.
Karuna (KRTX) Up 48% on $14B Buyout Offer From Bristol Myers
Bristol Myers (BMY) is set to acquire Karuna (KRTX) for $330 per share. This transaction is expected to close in the first half of 2024.
Bristol-Myers buying Karuna signals a biotech boom ahead: Jefferies
Karuna Therapeutics Inc (NASDAQ: KRTX) ended nearly 50% up on Friday after Bristol-Myers Squibb Co (NYSE: BMY) said it will buy the biopharmaceutical firm for $14 billion.
Biotech boom ahead in 2024, top Jefferies analyst predicts on heels of Bristol Meyers-Karuna deal
Michael Yee, Jefferies Senior Biotech Analyst, joins 'Fast Money' to talk a possible boom ahead for the biotech sector.
Bristol Myers Squibb to buy Karuna Therapeutics for $14 billion in cash
Stephanie Link and Jim Lebenthal join 'Halftime Report' to discuss Bristol Myers Squibb's latest announcement to buy Karuna Therapeutics for $14 billion.
Bristol Myers Squibb buys neurological drug developer Karuna Therapeutics in $14B deal
Shares of biopharmaceutical company Karuna Therapeutics skyrocketed more than 47% Friday morning after giant Bristol-Myers Squibb Co (NYSE:BMY, ETR:RM, OTC:BMYMP) announced a deal to acquire the company in a $14 billion cash deal. The agreement valued Karuna at $330 per share.
Midday Movers: Karuna Jumps on Deal With Bristol Myers Squibb, Nike Falls on Sales Outlook
U.S. equities headed into the long holiday weekend with gains at midday, amid a broad-based rally fueled by enthusiasm over the possibility of several Fed interest rate cuts next year. The Dow, S&P 500, and Nasdaq were all up.
Bristol Myers Squibb Boosts Its Neuroscience Reach With $14 Billion Karuna Deal
Karuna Therapeutics (KRTX) shares skyrocketed over 46% after Bristol Myers Squibb (BMY) said it would buy the biopharmaceutical firm for $14 billion to expand its neuroscience portfolio.
KRTX Financial details
KRTX Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 1.27 | 0.34 | 0.02 | |
Net income per share | -3.75 | -2.59 | -4.94 | -8.74 | -11.73 | |
Operating cash flow per share | -2.59 | -2.64 | -3.46 | -7.21 | -10.44 | |
Free cash flow per share | -2.6 | -2.66 | -3.57 | -7.24 | -10.52 | |
Cash per share | 32.56 | 12.19 | 16.95 | 35.54 | 34.17 | |
Book value per share | 32.61 | 12.82 | 17.23 | 35.61 | 33.94 | |
Tangible book value per share | 32.61 | 12.82 | 17.23 | 35.61 | 33.94 | |
Share holders equity per share | 32.61 | 12.82 | 17.23 | 35.61 | 33.94 | |
Interest debt per share | 0.1 | 0.1 | 0.26 | 0.62 | 0.45 | |
Market cap | 900.93M | 2.69B | 3.82B | 6.22B | 11.7B | |
Enterprise value | 692.21M | 2.64B | 3.62B | 5.97B | 11.53B | |
P/E ratio | -20.09 | -39.19 | -26.54 | -22.49 | -26.97 | |
Price to sales ratio | 0 | 0 | 103.27 | 584.29 | 17.89K | |
POCF ratio | -29.13 | -38.46 | -37.84 | -27.26 | -30.32 | |
PFCF ratio | -29.03 | -38.23 | -36.72 | -27.15 | -30.09 | |
P/B Ratio | 2.31 | 7.93 | 7.6 | 5.52 | 9.33 | |
PTB ratio | 2.31 | 7.93 | 7.6 | 5.52 | 9.33 | |
EV to sales | 0 | 0 | 97.87 | 561.45 | 17.63K | |
Enterprise value over EBITDA | -16.14 | -38.48 | -25.27 | -20.62 | -23.38 | |
EV to operating cash flow | -22.38 | -37.74 | -35.86 | -26.19 | -29.88 | |
EV to free cash flow | -22.3 | -37.51 | -34.8 | -26.09 | -29.66 | |
Earnings yield | -0.05 | -0.03 | -0.04 | -0.04 | -0.04 | |
Free cash flow yield | -0.03 | -0.03 | -0.03 | -0.04 | -0.03 | |
Debt to equity | 0 | 0.01 | 0.01 | 0 | 0.01 | |
Debt to assets | 0 | 0.01 | 0.01 | 0 | 0.01 | |
Net debt to EBITDA | 4.87 | 0.74 | 1.39 | 0.84 | 0.34 | |
Current ratio | 132.76 | 50.28 | 25.59 | 34.02 | 19.31 | |
Interest coverage | -48.05 | 0 | 0 | -20.43 | 0 | |
Income quality | 0.7 | 1.02 | 0.7 | 0.83 | 0.89 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 1.42 | 7.15 | 200.81 | |
Research and developement to revenue | 0 | 0 | 3.47 | 21.08 | 556.73 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0.01 | 0.03 | 0 | 0.01 | |
Capex to revenue | 0 | 0 | -0.08 | -0.09 | -4.46 | |
Capex to depreciation | -1.98 | -2.89 | -6.07 | -0.82 | -1.71 | |
Stock based compensation to revenue | 0 | 0 | 0.81 | 4.46 | 114.07 | |
Graham number | 52.45 | 27.34 | 43.74 | 83.66 | 94.66 | |
ROIC | -0.12 | -0.21 | -0.28 | -0.26 | -0.38 | |
Return on tangible assets | -0.11 | -0.2 | -0.27 | -0.24 | -0.32 | |
Graham Net | 32.3 | 11.86 | 16.48 | 34.81 | 32.49 | |
Working capital | 389.75M | 337.75M | 497.12M | 1.12B | 1.25B | |
Tangible asset value | 389.92M | 339.74M | 503.95M | 1.13B | 1.25B | |
Net current asset value | 389.6M | 335.91M | 491.69M | 1.12B | 1.23B | |
Invested capital | 0 | 0.01 | 0.01 | 0 | 0.01 | |
Average receivables | 0 | 0 | 875K | 903.5K | 2.48M | |
Average payables | 408K | 706K | 1.4M | 2.16M | 4.58M | |
Average inventory | 0 | 0 | 10.44M | 24.61M | 30.58M | |
Days sales outstanding | 0 | 0 | 17.28 | 1.96 | 2.73K | |
Days payables outstanding | 3.44K | 2.18K | 1.4K | 780.88 | 1.46K | |
Days of inventory on hand | 0 | 0 | 15.07K | 9.3K | 7.04K | |
Receivables turnover | 0 | 0 | 21.12 | 186.61 | 0.13 | |
Payables turnover | 0.11 | 0.17 | 0.26 | 0.47 | 0.25 | |
Inventory turnover | 0 | 0 | 0.02 | 0.04 | 0.05 | |
ROE | -0.12 | -0.2 | -0.29 | -0.25 | -0.35 | |
Capex per share | -0.01 | -0.02 | -0.11 | -0.03 | -0.08 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0.15 | 0.02 | 0 | 0 | 0 | |
Net income per share | -2.22 | -2.47 | -2.75 | -3.16 | -3.01 | |
Operating cash flow per share | -2.29 | -2.89 | -1.71 | -2.92 | -2.94 | |
Free cash flow per share | -2.3 | -2.91 | -1.73 | -2.94 | -2.96 | |
Cash per share | 32.67 | 42.31 | 38.28 | 35.59 | 33.42 | |
Book value per share | 32.73 | 42.76 | 37.83 | 35.08 | 33.2 | |
Tangible book value per share | 32.73 | 42.76 | 37.83 | 35.08 | 33.2 | |
Share holders equity per share | 32.73 | 42.76 | 37.83 | 35.08 | 33.2 | |
Interest debt per share | 0.43 | -0.19 | 0.42 | 0.41 | 0.75 | |
Market cap | 6.76B | 6.32B | 8.14B | 6.37B | 11.96B | |
Enterprise value | 6.52B | 5.76B | 7.89B | 6.2B | 11.79B | |
P/E ratio | -22.18 | -18.36 | -19.72 | -13.37 | -26.26 | |
Price to sales ratio | 1.28K | 9.67K | 0 | 0 | 0 | |
POCF ratio | -85.84 | -62.82 | -126.88 | -57.94 | -107.67 | |
PFCF ratio | -85.53 | -62.37 | -125.36 | -57.61 | -106.9 | |
P/B Ratio | 6 | 4.25 | 5.73 | 4.82 | 9.53 | |
PTB ratio | 6 | 4.25 | 5.73 | 4.82 | 9.53 | |
EV to sales | 1.23K | 8.81K | 0 | 0 | 0 | |
Enterprise value over EBITDA | -76.65 | -52.84 | -65.8 | -45.54 | -91.29 | |
EV to operating cash flow | -82.76 | -57.27 | -123.01 | -56.4 | -106.15 | |
EV to free cash flow | -82.45 | -56.87 | -121.55 | -56.08 | -105.39 | |
Earnings yield | -0.01 | -0.01 | -0.01 | -0.02 | -0.01 | |
Free cash flow yield | -0.01 | -0.02 | -0.01 | -0.02 | -0.01 | |
Debt to equity | 0 | 0 | 0.01 | 0.01 | 0.01 | |
Debt to assets | 0 | 0 | 0.01 | 0.01 | 0.01 | |
Net debt to EBITDA | 2.86 | 5.12 | 2.07 | 1.24 | 1.31 | |
Current ratio | 34.02 | 59.74 | 37.61 | 27.88 | 19.31 | |
Interest coverage | -8.89 | 9.49 | 0 | 0 | -11.28 | |
Income quality | 1.03 | 1.03 | 0.62 | 0.92 | 0.98 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 4.61 | 37.08 | 0 | 0 | 0 | |
Research and developement to revenue | 12.51 | 130.68 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0.01 | 0.01 | 0.01 | 0.01 | |
Capex to revenue | -0.05 | -1.09 | 0 | 0 | 0 | |
Capex to depreciation | -0.95 | -2.18 | -1.65 | -1.37 | -1.79 | |
Stock based compensation to revenue | 2.4 | 23.71 | 0 | 0 | 0 | |
Graham number | 40.39 | 48.78 | 48.37 | 49.95 | 47.44 | |
ROIC | -0.08 | -0.06 | -0.07 | -0.09 | -0.1 | |
Return on tangible assets | -0.07 | -0.06 | -0.07 | -0.09 | -0.09 | |
Graham Net | 32 | 41.5 | 36.88 | 34.13 | 31.79 | |
Working capital | 1.12B | 1.48B | 1.41B | 1.32B | 1.25B | |
Tangible asset value | 1.13B | 1.49B | 1.42B | 1.32B | 1.25B | |
Net current asset value | 1.12B | 1.48B | 1.4B | 1.3B | 1.23B | |
Invested capital | 0 | 0 | 0.01 | 0.01 | 0.01 | |
Average receivables | 69K | 28.5K | 0 | 2.45M | 4.9M | |
Average payables | 9.05M | 1.43M | 789K | 2.02M | 4.86M | |
Average inventory | 26.6M | 14.16M | 0 | 3.75M | 20.16M | |
Days sales outstanding | 0.97 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 702 | 131.01 | 211.47 | 577.53 | 1.37K | |
Days of inventory on hand | 8.36K | 0 | 0 | 1.47K | 6.61K | |
Receivables turnover | 92.6 | 0 | 0 | 0 | 0 | |
Payables turnover | 0.13 | 0.69 | 0.43 | 0.16 | 0.07 | |
Inventory turnover | 0.01 | 0 | 0 | 0.06 | 0.01 | |
ROE | -0.07 | -0.06 | -0.07 | -0.09 | -0.09 | |
Capex per share | -0.01 | -0.02 | -0.02 | -0.02 | -0.02 |
KRTX Frequently Asked Questions
What is Karuna Therapeutics, Inc. stock symbol ?
Karuna Therapeutics, Inc. is a US stock , located in Boston of Ma and trading under the symbol KRTX
Is Karuna Therapeutics, Inc. buy or a sell ?
6 stock analysts have 6 predictions with a medium analyst target price of $257.5. The lowest prediction is $150 and the highest is $330
What is KRTX stock prediction ?
What is Karuna Therapeutics, Inc. stock quote today ?
Karuna Therapeutics, Inc. stock price is $329.83 today.
Is Karuna Therapeutics, Inc. stock public?
Yes, Karuna Therapeutics, Inc. is a publicly traded company.